Illumina (ILMN)

Company ID: 248 | CIK: 0001110803
10-Q view:
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
Segments are charted by their disclosed metrics (revenue, segment profit, etc.). Each line is a single segment. Reconciliation/corporate items are excluded. Major customers are shown as a percentage of revenue. Operational KPIs are grouped by metric concept; sub-metrics appear as separate lines.

Geographic Segments

No 10-Q data

Business Unit / Product Segments

Major Customers (% of Revenue)

Operational KPIs

Backlog (backlog)

New services contracts (bookings)

No 10-K data

Oligonucleotide production capacity (capacity)

Temporary Employees (contractors)

No 10-Q data

Stockholders of record (customers)

No 10-Q data

Total employees (headcount)

Service contracts signed (orders_received)

Accumulated deficit (other)

No 10-K data

Applied market revenue share (other)

No 10-K data

Array share of revenue (other)

No 10-Q data

Auction rate securities (other)

No 10-K data

Available credit capacity (other)

No 10-K data

Available equipment financing (other)

No 10-K data

Available share repurchase authorization (other)

No 10-K data

BeadLab systems installed (other)

No 10-K data

BeadLabs installed (other)

No 10-K data

BeadStation systems shipped (other)

No 10-K data

Cash and investments (other)

No 10-K data

Cash and short-term investments (other)

No 10-K data

Cash from operations (other)

No 10-K data

Cash runway (other)

No 10-K data

Cash, cash equivalents and short-term investments (other)

No 10-K data

Closing stock price (other)

No 10-Q data

Common Stock Outstanding (other)

No 10-Q data

Common shares outstanding (other)

Common stock closing price (other)

No 10-K data

Common stock outstanding (other)

Construction progress payments (other)

No 10-K data

Consumable share of product revenue (other)

No 10-K data

Consumables revenue (other)

No 10-K data

Consumables revenue share (other)

No 10-Q data

Consumables share of product revenue (other)

No 10-Q data

Consumables share of revenue (other)

No 10-Q data

Contract assets (other)

No 10-K data

Contract liabilities (other)

No 10-K data

Convertible notes outstanding (other)

No 10-K data

Convertible notes principal outstanding (other)

No 10-K data

Covered revenue payments (other)

No 10-K data

Customer-authored papers (other)

No 10-Q data

Deferred revenue (other)

No 10-K data

Deferred revenue recognized (other)

No 10-K data

EC fine accrual (other)

No 10-K data

ESPP shares available (other)

No 10-K data

ESPP shares issued (other)

No 10-K data

Effective tax rate (other)

No 10-K data

Equity awards outstanding (other)

No 10-K data

Equity compensation plan information (other)

No 10-Q data

FX forward contract notional (other)

No 10-K data

Foreign exchange forward notional (other)

No 10-K data

GRAIL cash incentive awards outstanding (other)

No 10-K data

GRAIL contingent consideration fair value (other)

No 10-K data

GRAIL covered revenue payments (other)

No 10-K data

GRAIL covered revenues (other)

No 10-K data

GRAIL funding requirement (other)

No 10-K data

GRAIL ownership interest (other)

No 10-K data

GRAIL ownership retained (other)

No 10-K data

Genome Analyzer trade-in incentive (other)

No 10-K data

Genome sequencing consumable cost (other)

No 10-K data

Genotyping systems installed (other)

No 10-K data

Government grant revenue share (other)

No 10-K data

Government grants share of revenue (other)

No 10-K data

Grant revenue share (other)

No 10-K data

Gross margin (other)

No 10-K data

HapMap project revenue share (other)

No 10-K data

Helix ownership interest (other)

No 10-K data

Installed base growth (other)

No 10-K data

Instrument lead time (other)

No 10-K data

Instrument revenue (other)

No 10-K data

Instrument share of revenue (other)

No 10-Q data

International revenue share (other)

International share of revenue (other)

No 10-Q data

Inventory (other)

No 10-K data

Issued U.S. Patents (other)

No 10-Q data

Issued U.S. patents (other)

No 10-Q data

Issued non-U.S. patents (other)

No 10-Q data

Issued patents (other)

No 10-Q data

Issued patents outside U.S. (other)

No 10-Q data

Legal contingency accrual (other)

No 10-K data

Market value held by non-affiliates (other)

No 10-Q data

Minorities in U.S. workforce (other)

No 10-Q data

Minority representation in U.S. workforce (other)

No 10-Q data

NIH funding dependency (other)

No 10-K data

NIH grant funding remaining (other)

No 10-K data

NIH grants (other)

No 10-Q data

NIH-dependent revenue share (other)

No 10-K data

NIH-funded revenue exposure (other)

No 10-K data

NIH-funded revenue share (other)

No 10-K data

Net margin (other)

No 10-K data

New services contracts (other)

No 10-K data

Note conversions (other)

No 10-K data

Number of Reportable Segments (other)

Operating margin (other)

No 10-K data

Outstanding equity awards (other)

No 10-K data

Patent Applications Pending (other)

No 10-Q data

Patents Issued (other)

No 10-Q data

Pending U.S. Patent Applications (other)

No 10-Q data

Pending U.S. patent applications (other)

No 10-Q data

Pending non-U.S. patent applications (other)

No 10-Q data

Pending patent applications (other)

No 10-Q data

Pending patent applications outside U.S. (other)

No 10-Q data

Performance stock units outstanding (other)

No 10-K data

Product gross margin (other)

No 10-K data

Product revenue (other)

No 10-K data

Record holders of common stock (other)

No 10-Q data

Remaining goodwill allocated to GRAIL (other)

No 10-K data

Remaining repurchase authorization (other)

No 10-K data

Remaining share repurchase authorization (other)

No 10-K data

Repurchase authorization remaining (other)

No 10-K data

Restricted stock awards outstanding (other)

No 10-K data

Restricted stock outstanding (other)

No 10-K data

Restricted stock units outstanding (other)

No 10-K data

Restructuring liability (other)

No 10-K data

Revenue (other)

No 10-K data

Revenue by product type (other)

No 10-K data

Revenue from NIH funding (other)

No 10-K data

Revenue from customers outside U.S. (other)

Revenue from deferred contract liabilities (other)

No 10-K data

Revenue growth (other)

No 10-K data

Revenue growth constant currency (other)

No 10-K data

Revenue growth guidance (other)

No 10-K data

Revenue mix (other)

No 10-K data

Revenue mix — consumables (other)

No 10-Q data

Revenue mix — instruments (other)

No 10-Q data

Sequencing revenue share (other)

No 10-Q data

Sequencing share of revenue (other)

No 10-Q data

Service and other revenue (other)

No 10-K data

Service gross margin (other)

No 10-K data

Share repurchase authorization remaining (other)

No 10-K data

Shares available for future grant (other)

No 10-K data

Shares available for future grants (other)

No 10-K data

Shares available for grant (other)

No 10-K data

Shares available for grants (other)

No 10-K data

Shares available for issuance (other)

No 10-K data

Shares available for repurchase (other)

No 10-K data

Shares available under ESPP (other)

No 10-K data

Shares available under equity plans (other)

No 10-K data

Shares held by directors and officers (other)

No 10-Q data

Shares issued under ESPP (other)

No 10-K data

Shares outstanding (other)

Shares repurchased (other)

No 10-K data

Shares reserved for future issuance (other)

No 10-Q data

Stock options available for future grant (other)

No 10-Q data

Stock options available for grant (other)

No 10-K data

Stock options exercised (other)

No 10-K data

Stock options granted (other)

Stock options outstanding (other)

Stock repurchase authorization remaining (other)

No 10-K data

Stockholders of record (other)

No 10-Q data

Total revenue (other)

No 10-K data

U.S. Patent Applications Pending (other)

No 10-Q data

U.S. Patents Issued (other)

No 10-Q data

U.S. patent applications pending (other)

No 10-Q data

U.S. patents (other)

No 10-Q data

U.S. patents issued (other)

No 10-Q data

US patents (other)

No 10-Q data

Unrecognized compensation recognition period (other)

No 10-K data

Unrecognized share-based compensation (other)

No 10-K data

Unrecognized stock compensation (other)

No 10-K data

Unrecognized stock-based compensation (other)

No 10-K data

Unused equipment loan capacity (other)

No 10-K data

Venture fund commitments (other)

No 10-K data

Voluntary turnover rate (other)

No 10-Q data

Warrants outstanding (other)

No 10-K data

Warranty reserve (other)

No 10-K data

Warranty reserve balance (other)

No 10-K data

Weighted average diluted shares (other)

No 10-K data

Weighted-average shares (other)

No 10-K data

Women in workforce (other)

No 10-Q data

Revenue, Remaining Performance Obligation, Amount (rpo)

Leased square footage (square_footage)

BeadLabs Installed (units_shipped)

Human capital disclosures. Workforce totals and demographics are point-in-time. Flow metrics use the year-to-date period for 10-Q and full year for 10-K. Workforce actions (RIFs, restructurings, acquisition-related changes) are listed in the table at the bottom.

Workforce Totals

No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data

Demographics

No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data

Workforce Breakdowns

No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data

HCM Metrics — Point-in-Time

No point-in-time HCM metrics found.

HCM Metrics — Flow (Annual / YTD)

No 10-Q data

Workforce Actions

Period EndTypeStatusAffected% WorkforceAnnouncedExpected CompletionGeographySegment / FunctionChargeSourceNote
2026-06-28acquisition_additioncompleted2026-01-30GlobalProteomics (SomaLogic)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		SomaLogic and other specified assets acquired from Standard BioTools for $460M total purchase price; no headcount added disclosed. Purchase price allocation includes $171M goodwill attributed partly to assembled workforce. Transaction costs of $9M in YTD 2026 expensed in SG&A.
2026-06-28restructuringcompleted2023-01-01GlobalVariousUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		No pre-tax restructuring charges were recognized in Q2 2026 or YTD 2026 for the 2023 cost reduction initiative.
2026-06-28restructuringcompleted2025-01-01GlobalVariousUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		No pre-tax restructuring charges were recognized in Q2 2026 or YTD 2026 for the Q1 2025 incremental cost reduction initiative.
2026-06-28acquisition_additioncompleted2026-01-302026-01-30GlobalProteomicsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired SomaLogic and other specified assets from Standard BioTools. Employee headcount added is not explicitly disclosed.
2026-03-29restructuringin_progressUSD 1 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2026 pre-tax restructuring charge of $1 million for employee separation costs; relates to ongoing cost reduction initiatives (2023 program and incremental Q1 2025 initiative). No employee count disclosed.
2026-03-29restructuringcompletedUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Recognized $1 million pre-tax restructuring charges related to employee separation costs in Q1 2026. Employee count not disclosed.
2026-03-29acquisition_additioncompleted2026-01-30business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired SomaLogic on January 30, 2026. Headcount added not explicitly disclosed.
2025-12-28restructuringin_progress2025-03GlobalCompany-wideUSD 47 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Incremental cost reduction initiative implemented in Q1 2025 (exact announcement date not specified) including workforce reductions, stock-based compensation and non-labor spending optimization; MD&A describes an associated $100 million cost reduction program for 2025. Headcount affected not disclosed. Restructuring liability of $7 million remained at fiscal year-end; $47 million of charges recorded in 2025 ($26 million in SG&A, $16 million in R&D, remainder in cost of revenue).
2025-12-28acquisition_additioncompleted2025-06-222026-01-30GlobalProteomics / multiomicsUSD 350 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Stock Purchase Agreement signed 2025-06-22; transaction completed 2026-01-30 for $350 million cash plus royalty streams and up to $75 million in milestone payments; a separate IP portfolio was acquired 2026-01-30 for $50 million. Headcount added not disclosed. Completion occurred after fiscal year-end but before the 2026-02-11 filing date.
2025-12-28restructuringin_progress2025-03-31GlobalGlobalUSD 47 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Q1 2025 incremental cost reduction initiative including workforce reductions. Total pre-tax restructuring charges of $47 million recorded in 2025, primarily employee separation costs.
2025-12-28restructuringin_progressEmployee Severance [Member]USD 47,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-28restructuringin_progressOther Restructuring [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-28restructuringin_progressUSD 47,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-09-28restructuringin_progress2025-12-31GlobalCore Illumina (workforce reductions, stock-based compensation and non-labor spending optimization)USD 41 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Incremental cost reduction program implemented in Q1 2025 (no specific announcement date disclosed) to mitigate Greater China revenue/income reduction and NIH funding uncertainty; $41M YTD 2025 charges ($2M in Q3 2025), $4M accrued at 2025-09-28, substantially all employee separation costs expected paid by end of Q4 2025; number of employees affected not disclosed.
2025-09-28restructuringin_progressGlobalCore Illumina (workforce reductions, facility consolidation)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pre-existing 2023 cost reduction initiative still reflected in the restructuring liability roll-forward ($4M accrued at 2024-12-29, $4M at 2025-09-28); no charges recorded in 2025 and no employee counts disclosed.
2025-09-28restructuringin_progress2025-01-01USD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 2025 restructuring charges of $2 million recorded ($1M R&D, $1M SG&A). Part of incremental cost reduction initiative implemented in Q1 2025 involving workforce reductions and optimization of stock-based compensation.
2025-09-28restructuringin_progress2025-01-01USD 41 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2025 restructuring charges of $41 million recorded ($23M SG&A, $15M R&D, remainder in cost of revenue). Includes employee separation costs and optimization of non-labor spending.
2025-09-28restructuringin_progressEmployee Severance [Member]USD 41,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-28restructuringin_progressOther Restructuring [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-28restructuringin_progressUSD 41,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-29restructuringin_progress2025-12-31GlobalCore Illumina (all functions)USD 39 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Incremental cost reduction initiative implemented in Q1 2025 (announcement quarter only; no exact date given) covering stock-based compensation optimization, non-labor spending and workforce reductions, aimed at mitigating Greater China revenue impact and NIH funding uncertainty. $39M is total YTD 2025 restructuring charges (employee separation costs), of which $8M was recorded in Q2 2025; $19M remained accrued at 2025-06-29 with an estimated $3M still to be incurred. No number of employees affected disclosed. Background: a separate 2023 cost reduction initiative has cumulative charges of $253M since inception.
2025-06-29restructuringin_progress2025-01-012025-12-31GlobalCore IlluminaUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 2025 restructuring charges of $8 million primarily for employee separation costs. Part of incremental cost reduction initiative implemented in Q1 2025 to mitigate impact of China business reduction and NIH funding uncertainty. Substantially all employee separation charges expected to be incurred and paid by end of Q4 2025.
2025-06-29restructuringin_progress2025-01-012025-12-31GlobalCore IlluminaUSD 39 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2025 restructuring charges of $39 million primarily for employee separation costs. Includes Q2 charges of $8 million. Part of incremental cost reduction initiative implemented in Q1 2025.
2025-06-29restructuringin_progressEmployee Severance [Member]USD 39,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-29restructuringin_progressOther Restructuring [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-29restructuringin_progressUSD 39,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-30restructuringin_progress2025-01-012025-09-28GlobalCore Illumina (multiple functions)USD 31 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Incremental cost reduction initiative in Q1 2025 including workforce reductions; $18M in SG&A, $11M in R&D, remainder in cost of revenue. $15M estimated costs still to be incurred, substantially all expected to be paid by end of Q3 2025. Headcount affected not disclosed.
2025-03-30divestiture_reductioncompleted2024-06-242024-06-24GlobalGRAILother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Spin-Off of GRAIL completed June 24, 2024; GRAIL headcount removed from consolidated workforce. Number of employees affected not disclosed in this filing.
2025-03-30restructuringin_progress2025-03-302025-09-30GlobalCore IlluminaUSD 31 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Incremental cost reduction initiative implemented in Q1 2025 including workforce reductions to mitigate impact of China business reduction and NIH funding uncertainty. Employee separation costs of $31M recorded; substantially all expected to be incurred and paid by end of Q3 2025.
2025-03-30restructuringin_progressEmployee Severance [Member]USD 31,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-30restructuringin_progressOther Restructuring [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-30restructuringin_progressUSD 31,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-12-29restructuringin_progressGlobalCore IlluminaUSD 12 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cost reduction initiative implemented in Q2 2023 (workforce reductions, facility consolidation); only FY2024 activity extracted. FY2024 employee separation costs were $12M; total FY2024 restructuring charges were $62M, including $46M asset impairment and $4M other. Employees affected not disclosed.
2024-12-29plant_closurein_progressUnited States (Foster City, CA; San Diego, CA)Facilitiesrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Facility exit activities under the same cost reduction initiative. FY2024 right-of-use asset impairments of $12M (Foster City) and $19M (San Diego property), plus $14M Foster City leasehold improvement impairment; $100M of Foster City assets remained at year-end. Associated workforce reduction not quantified.
2024-12-29divestiture_reductioncompleted2024-06-24GlobalGRAIL segmentother
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Spin-Off of GRAIL completed June 24, 2024; approximately 85.5% of GRAIL shares distributed, 14.5% retained. GRAIL headcount transferred not disclosed; GRAIL results were not reported as discontinued operations.
2024-12-29acquisition_additioncompletedUnited StatesCore Illuminabusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Fluent BioSciences acquisition completed in Q3 2024 ($42M developed technology, $2M customer relationships recorded); headcount added not disclosed. Exact completion date not stated.
2024-12-29restructuringin_progress2023-06-30GlobalCore IlluminaUSD 62 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Cost reduction initiative implemented in Q2 2023 including workforce reductions and facility consolidation. 2024 charges of $62 million primarily consisted of asset impairments related to exit activities at leased facilities. Employee separation costs of $12 million were also recorded in 2024.
2024-12-29restructuringin_progressEmployee Severance [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-29restructuringin_progressOther Restructuring [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-29restructuringin_progressUSD 16,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-09-29restructuringin_progress2023-06-302024-12-31United StatesCompany-wideUSD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cost reduction initiative implemented in Q2 2023 (exact announcement date not disclosed; date shown is end of Q2 2023). YTD 2024 employee separation costs were $13M within total restructuring charges of $46M (remainder primarily facility asset impairments); Q3 2024 charges were $6M total, of which $5M in SG&A and $1M in R&D. Restructuring liability was $6M at 2024-09-29, with substantially all employee separation amounts expected paid by end of Q4 2024. No count of employees affected is disclosed.
2024-09-29divestiture_reductioncompleted2023-12-172024-06-24GlobalGRAIL segmentother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		GRAIL separated into a public company on 2024-06-24 via distribution of ~85.5% of GRAIL shares; Illumina retained ~14.5%. Disposition did not qualify as a discontinued operation, so results were not reclassified. No employee counts associated with the spin-off are disclosed.
2024-09-29acquisition_additioncompletedCore Illuminabusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Fluent BioSciences acquisition completed in Q3 2024; recorded $42M developed technology (7-year life) and $2M customer relationships (11-year life). No acquisition date or headcount added is disclosed in this filing.
2024-09-29restructuringin_progress2023-04-02GlobalGlobalUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 2024 charges of $6M primarily for employee separations. Program initiated in Q2 2023.
2024-09-29restructuringin_progress2023-04-02GlobalGlobalUSD 46 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2024 charges of $46M. Includes $32M asset impairment (Foster City/San Diego facilities) and $13M employee separations.
2024-09-29divestiture_reductioncompleted2024-06-242024-06-24GlobalGRAILother
f5-10q / Qwen3.6-27B-Q8_0		Spin-off of GRAIL completed June 24, 2024. Headcount removed from consolidation. No specific employee count disclosed.
2024-09-29restructuringin_progressEmployee Severance [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-29restructuringin_progressOther Restructuring [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-29restructuringin_progressUSD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30divestiture_reductioncompleted2023-12-172024-06-24GlobalGRAIL segmentother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Spin-off distributed ~85.5% of GRAIL shares on 2024-06-24; GRAIL employees, assets and liabilities deconsolidated. No employee count disclosed. Separation-related transaction costs of $37M in Q2 2024 ($52M YTD) recorded in SG&A.
2024-06-30restructuringin_progress2024-09-30GlobalCompany-wideUSD 7 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cost reduction initiative begun in Q2 2023 (workforce reductions, facility consolidation) continuing in YTD 2024. Employee separation costs: $3M in Q2 2024, $7M YTD 2024; restructuring liability of $3M at 2024-06-30, substantially all expected paid by end of Q3 2024. No employee counts disclosed.
2024-06-30restructuringin_progressUnited States (Foster City, CA and San Diego, CA)FacilitiesUSD 32 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		YTD 2024 asset impairment charges ($18M right-of-use assets, $14M leasehold improvements) tied to Foster City campus and a San Diego property; ~$139M of related assets remain. No workforce reduction count disclosed.
2024-06-30acquisition_additionannounced2024-07-09Fluent BioSciencesUSD 85 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Fluent BioSciences for $85M upfront cash plus contingent milestone consideration; no headcount added disclosed.
2024-06-30restructuringin_progress2023-04-012024-09-30United StatesGeneral and AdministrativeUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 2024 charges of $4M recorded in SG&A. Part of cost reduction initiative started in Q2 2023. Employee separation costs expected to be paid by end of Q3 2024.
2024-06-30restructuringin_progress2023-04-01United StatesGeneral and AdministrativeUSD 32 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2024 asset impairment charges of $32M related to leased facilities (Foster City and San Diego campuses). Recorded in SG&A.
2024-06-30divestiture_reductioncompleted2024-06-242024-06-24GlobalGRAILother
f5-10q / Qwen3.6-27B-Q8_0		Spin-off of GRAIL completed June 24, 2024. Headcount removed from consolidated workforce not explicitly quantified in filing.
2024-06-30restructuringin_progressEmployee Severance [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressOther Restructuring [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressUSD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progress2024-06-30USD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cost reduction initiative announced in Q2 2023 (exact announcement date not disclosed) including workforce reductions and facility consolidation. Q1 2024 charges: $4M employee separation, $32M asset impairment (Foster City campus ROU/leasehold improvements), $36M total ($35M in SG&A, $1M in R&D). Cumulative since inception: $52M separation, $132M impairment, $188M total. Restructuring liability fell from $18M to $10M; substantially all separation payments expected by end of Q2 2024. No employee count disclosed. No headcount impact quantified for the Foster City/San Diego facility consolidation; ~$142M of related assets remain.
2024-03-31divestiture_reductionannounced2023-12-172024-06-30GRAILMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Illumina announced on 2023-12-17 it will divest GRAIL; European Commission approved the divestment plan on 2024-04-12 (subsequent event). Target is to finalize divestiture terms by end of Q2 2024 via third-party sale or capital markets transaction. GRAIL must currently be operated separately from Illumina. No headcount figures disclosed for GRAIL or the divestiture.
2024-03-31layoffcompleted12024-03-22United StatesExecutive — S.V.P. Chief Marketing OfficerUSD 550,000 (units)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Position of S.V.P. Chief Marketing Officer eliminated effective 2024-03-22 (announcement date not stated). Severance of $550,000 (52 weeks of wages) plus 60 days' notice pay of $91,667 payable on or about 2024-04-19, and 12 months of COBRA premiums. Related restructuring charges are captured in the restructuring record above; this record captures the individual executive separation disclosed in the exhibit.
2024-03-31restructuringin_progress2023-06-30GlobalCore IlluminaUSD 36 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q1 2024 charges primarily consist of asset impairment charges related to leased facilities (Foster City and San Diego campuses). Cumulative charges since inception are $188 million. Employee separation costs recorded in Q1 were $4 million.
2024-03-31restructuringin_progressEmployee Severance [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressOther Restructuring [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressUSD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-12-31restructuringin_progress2024-03-31GlobalPrimarily Core IlluminaUSD 152 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cost reduction initiative implemented in Q2 2023 comprising employee separation costs of $48M, asset impairment charges of $100M and other costs of $4M; $122M recorded in SG&A, $24M in R&D, remainder in cost of revenue. Included facility exits (i3 San Diego campus fully exited; partial exit of Foster City, CA campus). Employee headcount affected not disclosed; substantially all separation costs expected to be incurred and paid by end of Q1 2024, with $8M estimated still to be incurred at year-end.
2023-12-31divestiture_reductionannounced2023-12-17GlobalGRAILItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Illumina announced on 2023-12-17 that it will divest GRAIL via a third-party sale or capital markets transaction per the EC Divestment Decision, with a goal of finalizing terms by end of Q2 2024; no assurance on ultimate timing. GRAIL employed approximately 1,340 full-time employees at 2023-12-31 but no headcount reduction figure was disclosed. GRAIL must continue to be held and operated separately under EC transitional measures.
2023-12-31acquisition_additioncompletedNot disclosedNot disclosedother
f5-10k / MiMo-V2.6-Flash-fp8-HTML		An acquisition completed in Q4 2023 (net cash paid of $29M, developed technology intangible of $19M recorded); acquired headcount not disclosed. Purchase price allocation still being finalized.
2023-12-31restructuringcompleted2023-06-302024-03-31GlobalCore IlluminaUSD 152 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Cost reduction initiative implemented in Q2 2023 including workforce reductions and facility consolidations. Total pre-tax charges of $152 million ($48 million employee separation, $100 million asset impairment, $4 million other). Employee separation costs expected to be incurred and paid by end of Q1 2024.
2023-12-31restructuringin_progressEmployee Severance [Member]USD 48,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressOther Restructuring [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressUSD 52,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-10-01restructuringin_progress2023-12-31GlobalCompany-wideUSD 33 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cost reduction initiative implemented in Q2 2023 covering workforce reductions, facility consolidation and other actions; no headcount affected disclosed. YTD 2023 employee separation costs were $33M (Q3 2023: $7M); substantially all separation charges expected incurred and paid by end of 2023. Total restructuring charges YTD 2023 were $91M including asset impairments.
2023-10-01plant_closurecompleted2023-09-30San Diego, CaliforniaCorporate facilities (i3 campus)USD 33 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Full exit of the i3 campus completed in Q3 2023, with $33M right-of-use asset impairment (YTD: $38M) plus $14M leasehold improvement impairment (YTD: $16M) recorded in SG&A. No employee count associated with the closure disclosed.
2023-10-01restructuringin_progress2023-04-022023-12-31GlobalCore IlluminaUSD 91 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cost reduction initiative implemented in Q2 2023 including workforce reductions and facility consolidation. YTD 2023 charges include $33M employee separation costs and $56M asset impairment. Substantially all separation charges expected to be incurred and paid by end of 2023.
2023-10-01restructuringin_progressEmployee Severance [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-10-01restructuringin_progressOther Restructuring [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-10-01restructuringin_progressUSD 35,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-07-02restructuringin_progress2023-12-31Global (includes planned exit of i3 campus, San Diego, California; options under evaluation for Foster City, California campus)Company-wide cost reduction initiative; charges recorded across cost of revenue, R&D and SG&AUSD 33 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2023 pre-tax charge of $33M: $25M employee separation, $7M asset impairment (mainly ROU assets and leasehold improvements), $1M other; $18M in SG&A, $12M in R&D, remainder in cost of revenue. $24M accrued at July 2, 2023 with $7M of estimated costs still to be incurred; substantially all separation charges expected incurred and paid by end of 2023. Number of employees affected not disclosed. Announcement date not specified beyond 'in Q2 2023'.
2023-07-02restructuringin_progress2023-07-022023-12-31GlobalCore IlluminaUSD 33 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 2023 cost reduction initiative including workforce reductions and facility consolidation. Total pre-tax charge of $33 million ($25 million employee separation, $7 million asset impairment, $1 million other). Employee separation costs expected to be incurred and paid by end of 2023. Specific headcount not disclosed.
2023-07-02restructuringin_progressEmployee Severance [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-07-02restructuringin_progressOther Restructuring [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-07-02restructuringin_progressUSD 26,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-01-01restructuringin_progressGlobalCore Illumina — Research and DevelopmentUSD 6 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Recorded in Q4 2022, primarily employee severance costs; no employee count, announcement date, or completion timeline disclosed.
2023-01-01restructuringin_progressGlobalCore Illumina — Selling, General and AdministrativeUSD 24 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Recorded in Q4 2022; primarily employee severance costs plus a lease impairment charge, so the charge is not purely severance. No employee count or completion timeline disclosed.
2023-01-01acquisition_additioncompletedUnited StatesUnspecifiedMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		An acquisition completed in Q2 2022 (developed technology intangible of $23 million and database intangible of $12 million); headcount added not disclosed. The GRAIL acquisition closed August 18, 2021, in the prior fiscal year, and is not counted here.
2023-01-01restructuringcompleted2022-10-022022-12-31GlobalCore IlluminaUSD 24 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Q4 2022 restructuring charges consisting primarily of employee severance costs and a lease impairment charge.
2023-01-01restructuringcompleted2022-10-022022-12-31GlobalCore IlluminaUSD 6 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Q4 2022 R&D restructuring charges consisting primarily of employee severance costs.
2022-01-02acquisition_additioncompleted2021-08-182021-08-18Global (majority Americas)GRAIL segmentbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		GRAIL acquired 2021-08-18 and became a separate reportable segment. No explicit headcount-added figure is stated; GRAIL's workforce as of 2022-01-02 was approximately 700 full-time and 300 temporary employees. Also references $615M of post-combination accelerated share-based compensation and replacement awards for GRAIL employees.
2022-01-02acquisition_additioncompleted1,0002021-08-182021-08-18GlobalGRAILItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of GRAIL added approximately 700 full-time and 300 temporary employees.
2021-10-03acquisition_additioncompleted2021-08-182021-08-18United StatesGRAIL segment (new reportable segment)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition closed 2021-08-18; GRAIL operates as a separate reportable segment. Filing discloses goodwill attributable to assembled workforce but no employee headcount added. GRAIL held separate during European Commission merger review.
2021-10-03acquisition_additioncompleted2021-08-18GRAILbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of GRAIL completed on August 18, 2021. Specific headcount added is not disclosed, but significant share-based compensation expense ($615 million) was recognized for accelerated equity awards attributable to the post-combination period.
2021-07-04acquisition_additioncompletedother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		An unnamed acquisition closed in Q2 2021, adding $69 million of goodwill and a $35 million IPR&D intangible asset plus a $14 million contingent consideration liability; no headcount added disclosed
2021-01-03acquisition_additionannounced2020-09-20GlobalClinical Genomicsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Pending $8 billion acquisition ($3.5B cash / $4.5B stock) announced 2020-09-20; expected to close in second half of 2021 subject to regulatory approvals. Headcount to be added not disclosed; no restructuring or RIF activity disclosed for fiscal 2020.
2019-12-29divestiture_reductioncompleted2019-04-252019-04-25United StatesConsolidated VIEs (Helix)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Illumina sold its interest in and relinquished control of Helix on 2019-04-25, deconsolidating Helix's workforce from reported headcount; number of employees removed not disclosed. Recorded a $39 million gain on deconsolidation in other income, net.
2019-09-29divestiture_reductioncompleted2019-04-252019-04-25United StatesHelix (consumer genomics segment)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Illumina relinquished control of Helix and deconsolidated it effective April 25, 2019; Helix employees left the consolidated reporting entity. No employee count, severance, or restructuring charge disclosed; recorded a $39 million gain on deconsolidation in other (expense) income, net.
2018-12-30acquisition_additioncompleted2018-05-14United StatesCore Illuminabusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Edico Genome for $100 million cash net of cash acquired; headcount added not disclosed
2018-12-30acquisition_additionannounced2018-11-012019-06-30United StatesCore Illuminabusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Merger agreement to acquire Pacific Biosciences for approximately $1.2 billion cash ($8.00/share); expected to close mid-2019; headcount added not disclosed
2017-01-01othercompleted12016-10-312017-01-31United StatesExecutive — Chief Commercial OfficerUSD 810,000 (units)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Executive separation agreement filed as exhibit; severance equals 18 months of wages, plus 18 months COBRA continuation; transition period began 2016-10-31 and employment ends 2017-01-31 (after fiscal year end, before filing date)
2017-01-01acquisition_additioncompleted2016-01-31USD 18 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Two acquisitions closed in January 2016 with $17.8 million upfront cash, equity instruments and contingent consideration; headcount added through these acquisitions not disclosed
2016-01-03acquisition_additioncompleted2015-08CanadaSoftware / Laboratory information management systemsItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of GenoLogics Life Sciences Software Inc. completed August 2015; headcount added not disclosed. Net cash paid for all 2015 acquisitions was $36.6 million (investing activities).
2016-01-03acquisition_additioncompleted2016-01USD 18 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Two acquisitions closed January 2016 (after fiscal year-end, before filing) with $18 million upfront cash plus equity and contingent consideration up to approximately $49 million; headcount added not disclosed.
2014-12-28acquisition_additioncompleted2014-07-01United StatesRegulatory, quality, and molecular/companion diagnostics leadershipItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Myraqa, Inc. acquired in July 2014; no headcount added or purchase price detail disclosed for this acquisition in the filing.
2014-09-28acquisition_additioncompleted2014-07-31United StatesRegulatory, quality, and molecular diagnostics functionsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Myraqa, Inc. acquired in July 2014; the filing states the deal bolstered regulatory and quality capabilities but discloses no employee count added. Goodwill of $3.3 million was recorded for the current-period acquisition in the goodwill roll-forward.
2013-12-29acquisition_additioncompleted2013-02-212013-02-21United StatesReproductive health / Diagnosticsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Verinata Health completed 2013-02-21 for aggregate purchase price of $396.3 million; acquired headcount not disclosed.
2013-12-29acquisition_additioncompleted2013-07-012013-07-01United StatesR&D / Sample preparationbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Advanced Liquid Logic completed July 2013 (digital microfluidics and liquid handling); exact closing date and acquired headcount not disclosed.
2013-12-29acquisition_additioncompleted2013-11-012013-11-01United StatesInformatics / Softwarebusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of NextBio completed November 2013 (clinical and genomic informatics); purchase price allocation is preliminary. Exact closing date and acquired headcount not disclosed. A fourth unnamed development-stage company was also acquired in 2013 with no headcount disclosed.
2013-12-29restructuringcompleted2011-12-312012-12-30GlobalUSD 4 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Restructuring plan announced in late 2011 to reduce global workforce and consolidate facilities. Activities completed during fiscal 2012. Fiscal 2013 charge of $3.5 million comprised primarily of severance pay and other employee separation costs.
2013-12-29acquisition_additioncompleted2013-02-212013-02-21business_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Verinata Health, Inc. completed February 21, 2013. Headcount added not explicitly quantified in filing.
2013-12-29acquisition_additioncompleted2013-12-292013-12-29business_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisitions of Advanced Liquid Logic Inc., NextBio, and another development-stage company completed during 2013. Headcount added not explicitly quantified in filing.
2013-09-29acquisition_additioncompleted2013-02-21United StatesReproductive health / NIPTUSD 396 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Aggregate purchase price $396.3M; headcount added not disclosed. 0.4M unvested Verinata stock options converted to Illumina options.
2013-09-29acquisition_additioncompleted2013-07-01United StatesLiquid handling solutionsUSD 97 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired July 1, 2013; purchase price $97.2M per MD&A; headcount added not disclosed.
2013-09-29acquisition_additionannounced2013-10-28United StatesClinical and genomic informaticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent-event acquisition completed October 28, 2013, after quarter end; purchase price and headcount not disclosed.
2013-09-29restructuringcompleted2011-12-31GlobalUSD 3 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Restructuring plans announced in late 2011 to reduce global workforce and consolidate facilities. Charges of $3.4 million recorded in the first three quarters of 2012 comprised primarily of severance pay and other employee separation costs. No restructuring charges were recorded in the current period (Q3 2013 or YTD 2013).
2013-06-30acquisition_additioncompleted2013-02-21United StatesReproductive health / prenatal testingUSD 396 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Aggregate purchase price $396.3M; no employee headcount added disclosed. Unvested Verinata options converted to 0.4M Illumina options.
2013-06-30acquisition_additioncompleted2013-03-31Development-stage companybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Development-stage company acquired during Q1 2013; recorded $6.0M goodwill and $15.6M developed technology. No headcount or target name disclosed.
2013-06-30acquisition_additionannounced2013-07-01United StatesLiquid handling solutionsUSD 96 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired Advanced Liquid Logic Inc. for up to $96.0M in cash; no employee headcount disclosed.
2013-06-30restructuringcompleted2011-12-31GlobalUSD 3 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Restructuring plans announced in late 2011 to reduce global workforce and consolidate facilities. $3.3 million charges recorded in first half of 2012 (prior year comparison); no charges in current period.
2013-03-31acquisition_additioncompleted2013-02-21United StatesReproductive health diagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Verinata Health completed 2013-02-21; headcount added not disclosed. Converted 0.4 million unvested Verinata stock options into Illumina options.
2013-03-31restructuringcompleted2011-12-31GlobalUSD 2,622 (thousands)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Restructuring charges of $2.6 million recorded in Q1 2012 (comparative period) comprised primarily of severance pay and other employee separation costs from plans announced in late 2011. No employee count disclosed.
2013-03-31restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-12-30restructuringcompleted200GlobalUSD 4 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program announced in late 2011 (exact date not stated); approximately 200 employees notified of involuntary termination is cumulative since inception, not FY2012-only. FY2012 additional expense was $3.5 million; cumulative program cost $11.7 million; severance liability fully settled (zero balance) at 2012-12-30.
2012-12-30acquisition_additioncompleted2012-09-19United KingdomDiagnostics / reproductive health screeningbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of BlueGnome Ltd. for $95.5 million total consideration; acquired headcount not disclosed in the filing.
2012-12-30acquisition_additionannounced2013-01-06United StatesDiagnostics / non-invasive prenatal testingsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Verinata Health for $350 million cash plus up to $100 million in milestone payments through 2015; announced after fiscal year-end (2012-12-30) and before filing date; acquired headcount not disclosed.
2012-12-30restructuringcompleted2008%2011-10-01GlobalUSD 12 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Announced in late 2011 (Q4 FY2011). Approximately 200 employees notified of involuntary termination. Cumulative expense recorded since inception is $11.658 million. As of Dec 30, 2012, accrued liabilities are zero, indicating completion.
2012-12-30restructuringin_progressUSD 3,522,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-30restructuringin_progressFacility Closing [Member]USD 221,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-30restructuringin_progressEmployee Severance [Member]USD 2,780,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-30restructuringin_progressOther Restructuring [Member]USD 521,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-09-30restructuringin_progress2002011GlobalCompany-wide (workforce reductions and facilities consolidation)USD 12 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approximately 200 employees notified of involuntary termination under the late-2011 cost reduction initiative. Cumulative pre-tax expense since inception was $11.57M, with $3.434M recorded in the nine months ended 2012-09-30; estimated total program cost $11.673M. MD&A states the effort is substantially completed; $0.358M remained accrued at 2012-09-30.
2012-09-30plant_closurecompleted20112012-09-30United States (San Diego, California)Corporate headquartersUSD 23 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Headquarters relocation completed during Q3 2012; $22.8M additional facility exit obligation accrued (cease-use loss on former headquarters), bringing the obligation to $44.9M at 2012-09-30. Q3 headquarter relocation expense of $19.5M included cease-use loss, double rent and accelerated depreciation. No employee count tied to the move is disclosed.
2012-09-30acquisition_additioncompleted2012-09-19United Kingdom (BlueGnome Ltd.)Cytogenetics and in vitro fertilization screening productsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Total consideration $95.5M ($88.0M cash plus $7.5M fair value of contingent consideration up to $20.0M). Headcount acquired is not disclosed; up to $20.0M of retention-related contingent payments to shareholders/key employees will be expensed as contingent compensation through 2014-12-28.
2012-09-30restructuringin_progress2002011-12-31GlobalUSD 3,434 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Initiated in late 2011; approximately 200 employees notified of involuntary termination. YTD 2012 charges of $3.4 million primarily for severance and separation costs.
2012-09-30acquisition_additioncompleted2012-09-19USD 95,500 (thousands)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of BlueGnome Ltd. completed. Headcount not explicitly disclosed.
2012-09-30restructuringin_progressUSD 138,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-30restructuringin_progressEmployee Severance And Employee Relocation Costs [Member]USD 2,692,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-30restructuringin_progressOther Restructuring [Member]USD 521,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-30restructuringin_progressFacility Closing [Member]USD 221,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-07-01restructuringin_progress2002011Not specifiedGlobal workforce and facilitiesUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approximately 200 employees notified of involuntary termination under late-2011 cost reduction initiative; $3.3M additional charges recorded in six months ended 2012-07-01, cumulative expense $11.4M of estimated $13.9M total; $0.6M accrual remains at quarter-end; includes workforce reductions and facility consolidations
2012-07-01restructuringin_progress2002011-12-31GlobalUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan announced in late 2011. Approximately 200 employees notified of involuntary termination. YTD 2012 charges of $3.3M primarily for severance and separation costs.
2012-07-01restructuringin_progressUSD 674,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-07-01restructuringin_progressFacility Closing [Member]USD 221,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-07-01restructuringin_progressOther Restructuring [Member]USD 537,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-07-01restructuringin_progressEmployee Severance And Employee Relocation Costs [Member]USD 2,538,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-04-01restructuringin_progress2002011GlobalNot specifiedUSD 2,622 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approximately 200 employees notified of involuntary termination under a late-2011 cost reduction initiative; Q1 2012 charge of $2,622 thousand was primarily severance and separation costs. Estimated total program cost of $13,855 thousand, including $1,500 thousand of facilities exit costs; cumulative expense since inception was $10,758 thousand at quarter end.
2012-04-01restructuringin_progress2002011-12-31GlobalUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Initiated in late 2011; approximately 200 employees notified of involuntary termination. Q1 2012 charges of $2.6M primarily related to severance and separation costs.
2012-04-01restructuringin_progressUSD 2,622,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-04-01restructuringin_progressFacility Closing [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-04-01restructuringin_progressEmployee Severance And Employee Relocation Costs [Member]USD 2,257,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-04-01restructuringin_progressOther Restructuring Charges [Member]USD 365,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-01-01restructuringin_progress2008%2011-10-252012-06-30GlobalUSD 8 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Charge recorded in Q4 2011: $7.7M employee separation plus $0.5M other; estimated total program cost $13.8M including $1.6M facilities exit costs. Additional charges expected through Q2 2012. Filer states approximately 8% of workforce; 200 vs. ~2,200 total implies roughly 9%.
2012-01-01acquisition_additioncompleted2011-01-10United StatesLife Sciences (sample preparation reagents and specialty enzymes)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Epicentre Technologies Corporation completed 2011-01-10 for $71.4M total consideration; headcount added through the acquisition is not disclosed.
2012-01-01restructuringin_progress2008%2011-10-252012-06-30GlobalUSD 8 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Announced reduction of global workforce by approximately 200 employees (8%) and consolidation of facilities. Recorded $8.1 million charge in Q4 2011. Expected to incur additional charges through Q2 2012.
2012-01-01restructuringin_progress200USD 8,136,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-01-01restructuringin_progressEmployee Severance And Employee Relocation Costs [Member]USD 7,683,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-01-01restructuringin_progressFacility Closing [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-01-01restructuringin_progressOther Restructuring Charges [Member]USD 453,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-10-02restructuringannounced2008%2011-10-25GlobalUSD 15 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter announcement (October 25, 2011) to cut approximately 200 employees, about 8% of the global workforce; expected charge of $15-17 million, primarily severance and benefits, with the majority to be recorded and paid in Q4 fiscal 2011. Disclosed in both the subsequent-events note and MD&A; extracted once from the footnote. Implied workforce total of ~2,500 from the 200/8% figures is not otherwise confirmed in the filing.
2011-10-02restructuringannounced2008%2011-10-252011-12-31GlobalUSD 16 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Announced reduction of global workforce by approx. 200 employees (8%). Charge of $15-17 million expected, majority recorded/paid in Q4 FY2011.
2011-07-03acquisition_additioncompleted2011-01-10United StatesR&D / consumables (sample preparation reagents and specialty enzymes)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Epicentre acquisition closed 2011-01-10; total consideration $71.4M. Filing does not disclose headcount added; approximately 229,000 shares issued to Epicentre shareholders, one third treated as purchase price and the remainder as post-acquisition service compensation over two years.
2011-04-03acquisition_additioncompleted2011-01-10United StatesR&D / Sample Preparationbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Epicentre acquisition closed 2011-01-10 for $72.5M total consideration; headcount added not disclosed. 229,000 shares issued to Epicentre shareholders subject to milestone forfeiture.
2011-01-02acquisition_additioncompleted2010-04-302010-04-30United StatesLife Sciences (real-time PCR product line)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Helixis completed for approximately $86.7 million total consideration; headcount added not disclosed.
2011-01-02acquisition_additioncompleted2010-07-282010-07-28United StatesResearch and development (development-stage entity)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of a privately held development-stage entity for $22.0 million; $21.4 million capitalized as in-process R&D; headcount added not disclosed.
2011-01-02acquisition_additioncompleted2011-01-102011-01-10United States (Wisconsin)Life Sciences (sample preparation reagents and specialty enzymes)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Post-fiscal-year-end acquisition of Epicentre Biotechnologies: $60 million cash, $15 million stock subject to forfeiture, up to $15 million contingent consideration; headcount added not disclosed.
2010-10-03acquisition_additioncompleted2010-04-30United StatesLife Sciencesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Helixis, Inc. (real-time PCR systems) closed 2010-04-30 for ~$86.7M total consideration; operations consolidated from acquisition date. No employee headcount added or retained was disclosed.
2010-07-04acquisition_additioncompleted2010-04-30USD 87 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Helixis, Inc. completed on April 30, 2010. Total consideration approx $86.7 million. Employee count not disclosed.
2010-01-03voluntary_separationannounced12010-02-28United StatesLife Sciences (Senior Vice President & General Manager)USD 259,544 (dollars)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Post-fiscal-year-end subsequent event: executive resignation effective 2010-02-28 with lump-sum severance of $259,544.08, COBRA payments through 2010-09-30, extended option exercise periods, and vesting acceleration of options through 2010-08-28. Agreement date not stated in the exhibit.
2008-12-28acquisition_additioncompleted2008-08-012008-08-01United StatesLife Sciences / SequencingUSD 25 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Avantome completed 2008-08-01 for $25.8M cash plus up to $35.0M contingent consideration; headcount added not disclosed. Charge shown is acquired IPR&D write-off.
2008-09-28acquisition_additioncompleted2008-08-01USD 26 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Avantome, Inc. completed August 1, 2008. Cash consideration of $25.8 million paid. Headcount not disclosed.
2008-06-29acquisition_additionannounced2008-07-22Development-stage sequencing technology (Avantome, Inc.)USD 25 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cash consideration of $25.0M paid up front plus up to $35.0M contingent on milestones; headcount added not disclosed.
2008-06-29acquisition_additionannounced2008-07-22USD 25 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Avantome, Inc. announced July 22, 2008. Upfront cash payment of $25.0 million. No headcount disclosed.
2007-12-30acquisition_additioncompleted2006-11-122007-01-26United StatesSequencingUSD 303 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Stock-for-stock merger completed 2007-01-26; approximately 13.1 million Illumina shares issued. Filer does not disclose Solexa employee headcount added; approximately 3.7 million shares of restricted stock, options and warrants were assumed. Associated $303.4 million charge is acquired in-process R&D, not severance.
2007-12-30acquisition_additioncompleted2007-01-262007-01-26GlobalAllbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Solexa completed on January 26, 2007. Specific headcount added not disclosed, but total employee count increased significantly.
2007-07-01acquisition_additioncompleted2006-11-122007-01-26United States (Hayward, CA; Little Chesterford, UK)All functions (sequencing, genotyping, gene expression)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Stock-for-stock merger completed 2007-01-26; Solexa results consolidated from that date. No employee headcount added disclosed. Approximately 3.7 million shares of restricted stock, options and warrants assumed; ~$14.7 million of unvested stock compensation to be recognized over ~2 years as a retention-related item.
2007-04-01acquisition_additioncompleted2007-01-262007-01-26United States; United KingdomGenetic analysis technologies (sequencing)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Stock-for-stock merger completed January 26, 2007; approximately 13.1 million Illumina shares issued. Headcount added through the acquisition was not disclosed. Related: approximately $7.9 million change-in-control bonuses to certain Solexa executives and roughly 3.7 million assumed options, warrants and restricted shares.
2007-04-01acquisition_additioncompleted2007-01-26United States; United Kingdombusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Completed acquisition of Solexa, Inc. on January 26, 2007. Results of operations included since acquisition date. Specific headcount added not disclosed.
2006-12-31acquisition_additioncompleted2006-11-122007-01-26United StatesDNA sequencingsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Stock-for-stock merger completed 2007-01-26 (after fiscal year-end, before filing date); approximately 13.1 million Illumina shares issued at 0.344 exchange ratio. Solexa headcount not disclosed. Definitive securities purchase agreement and $50 million investment in Solexa entered into 2006-11-12.
2006-01-01acquisition_additioncompleted2005-02-222005-04-08Connecticut, United StatesDigital microbead platform / research and developmentUSD 16 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Illumina acquired 100% of CyVera on 2005-04-08 (1.6M shares plus $2.3M cash, total purchase price $17.8M); $15.8M of purchase price expensed as acquired in-process R&D. Filer does not disclose CyVera headcount added.
2005-10-02acquisition_additioncompleted2005-02-222005-04-08United States (Connecticut)Research and Development / Operationsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Illumina acquired 100% of CyVera Corporation on 2005-04-08; headcount added not disclosed in filing.
2005-10-02acquisition_additioncompleted2005-04-08ConnecticutResearch and Developmentbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired 100% of CyVera Corporation. Filing states 'hired certain employees of CyVera' but does not disclose specific headcount numbers.
2005-07-03acquisition_additioncompleted2005-02-222005-04-08United States (Connecticut)CyVera Corporation (digital microbead technology platform)USD 16 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger closed 2005-04-08; CyVera results consolidated from that date. Purchase price $17.8M including $15.8M in-process R&D charge. Filing discloses shares issued (1,579,897), cash paid, and assumed options/liabilities, but no employee headcount added.
2005-07-03acquisition_additioncompleted2005-02-222005-04-08USD 17,846 (thousands)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of CyVera Corporation completed April 8, 2005. Total purchase price $17.8 million. Filing states 'hired certain employees of CyVera' but does not disclose specific headcount added.
2005-04-03acquisition_additioncompleted2005-04-082005-04-08United States (Connecticut)USD 18 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter acquisition of CyVera Corporation; consideration $17.5M (approx. 1.6M shares plus $2.3M of assumed liabilities). Employee count added not disclosed; significant portion of purchase price expected to be charged to in-process R&D in Q2 2005.
2005-04-03acquisition_additioncompleted2005-04-08Connecticutsubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of CyVera Corporation completed; assumed certain liabilities and hired certain employees.
2005-01-02acquisition_additionannounced2005-022005-03-31Connecticut, United StatesResearch and Development / Technology (BeadArray)USD 18 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive merger agreement to acquire CyVera Corporation signed February 2005; aggregate consideration of $17.5 million comprising approximately 1.5 million shares plus payment of about $2.3 million of CyVera liabilities at closing. Headcount added not disclosed; charge shown is total transaction consideration, not a severance or restructuring charge.
2005-01-02acquisition_additionannounced2005-022005-03-31Connecticut, United Statessubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Merger agreement with CyVera Corporation signed February 2005 for $17.5 million in stock plus assumed liabilities; headcount added not disclosed.